Aurinia Stock: Lupkynis Growth And AUR200 Pipeline Justify Buy Rating (AUPH)

Group 1 - Aurinia Pharmaceuticals (NASDAQ: AUPH) stock is experiencing a slow month with double-digit losses, potentially indicating profit-taking after stronger double-digit gains over the past six months [1] - The anticipated market movements in the coming month may influence investor sentiment and trading strategies [1] Group 2 - The article highlights the author's extensive background in financial analysis and investment research, emphasizing a strong track record in providing actionable trading ideas and well-researched investment recommendations [1] - The author is focused on building a new international investment portfolio and aims to share insights and strategies with the global investing community [1]